6.45 USD
+0.13 (+2.06%)
Overall CSBR gets a fundamental rating of 5 out of 10. We evaluated CSBR against 57 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of CSBR while its profitability can be described as average. CSBR has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
CSBR had positive earnings in the past year.
CSBR had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CSBR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CSBR reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.66%, CSBR belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
Looking at the Return On Equity, with a value of 84.15%, CSBR belongs to the top of the industry, outperforming 98.25% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 30.30%, CSBR belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.66% | ||
| ROE | 84.15% | ||
| ROIC | 30.3% |
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CSBR's Profit Margin of 5.19% is fine compared to the rest of the industry. CSBR outperforms 71.93% of its industry peers.
CSBR's Profit Margin has improved in the last couple of years.
With a Operating Margin value of 5.29%, CSBR perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
In the last couple of years the Operating Margin of CSBR has grown nicely.
CSBR has a Gross Margin (48.47%) which is in line with its industry peers.
In the last couple of years the Gross Margin of CSBR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.29% | ||
| PM (TTM) | 5.19% | ||
| GM | 48.47% |
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CSBR is creating value.
Compared to 1 year ago, CSBR has more shares outstanding
Compared to 5 years ago, CSBR has more shares outstanding
Compared to 1 year ago, CSBR has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.37, we must say that CSBR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CSBR (0.37) is worse than 71.93% of its industry peers.
CSBR has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
CSBR has a better Debt to FCF ratio (0.03) than 92.98% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that CSBR is not too dependend on debt financing.
The Debt to Equity ratio of CSBR (0.02) is better than 64.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 0.37 |
ROIC/WACC2.91
WACC10.41%
2.3 Liquidity
A Current Ratio of 0.93 indicates that CSBR may have some problems paying its short term obligations.
With a Current ratio value of 0.93, CSBR is not doing good in the industry: 91.23% of the companies in the same industry are doing better.
A Quick Ratio of 0.93 indicates that CSBR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.93, CSBR is doing worse than 85.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.93 |
3. Growth
3.1 Past
CSBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 3200.00%, which is quite impressive.
CSBR shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 146.62% yearly.
The Revenue has grown by 13.54% in the past year. This is quite good.
CSBR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.13% yearly.
EPS 1Y (TTM)3200%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)13.54%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%11.5%
3.2 Future
The Earnings Per Share is expected to decrease by -41.69% on average over the next years. This is quite bad
The Revenue is expected to grow by 18.26% on average over the next years. This is quite good.
EPS Next Y-50.13%
EPS Next 2Y-41.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.84%
Revenue Next 2Y8.88%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 19.55, CSBR is valued on the expensive side.
Based on the Price/Earnings ratio, CSBR is valued cheaper than 89.47% of the companies in the same industry.
When comparing the Price/Earnings ratio of CSBR to the average of the S&P500 Index (26.22), we can say CSBR is valued slightly cheaper.
With a Price/Forward Earnings ratio of 42.16, CSBR can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CSBR is valued a bit cheaper than the industry average as 61.40% of the companies are valued more expensively.
CSBR is valuated expensively when we compare the Price/Forward Earnings ratio to 23.58, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.55 | ||
| Fwd PE | 42.16 |
4.2 Price Multiples
82.46% of the companies in the same industry are more expensive than CSBR, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CSBR is valued cheaply inside the industry as 96.49% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.35 | ||
| EV/EBITDA | 16.89 |
4.3 Compensation for Growth
The decent profitability rating of CSBR may justify a higher PE ratio.
CSBR's earnings are expected to decrease with -41.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.69%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CSBR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:CSBR (12/18/2025, 11:14:42 AM)
6.45
+0.13 (+2.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners47.61%
Inst Owner Change-1.9%
Ins Owners26.74%
Ins Owner Change0%
Market Cap88.95M
Revenue(TTM)56.94M
Net Income(TTM)2.95M
Analysts82.86
Price Target12.24 (89.77%)
Short Float %0.76%
Short Ratio5.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)180.88%
Min EPS beat(2)65.69%
Max EPS beat(2)296.08%
EPS beat(4)4
Avg EPS beat(4)1095.34%
Min EPS beat(4)65.69%
Max EPS beat(4)3629.41%
EPS beat(8)7
Avg EPS beat(8)599.88%
EPS beat(12)8
Avg EPS beat(12)365.32%
EPS beat(16)10
Avg EPS beat(16)266.15%
Revenue beat(2)2
Avg Revenue beat(2)1.19%
Min Revenue beat(2)0.83%
Max Revenue beat(2)1.54%
Revenue beat(4)4
Avg Revenue beat(4)8.21%
Min Revenue beat(4)0.83%
Max Revenue beat(4)29.17%
Revenue beat(8)6
Avg Revenue beat(8)2.62%
Revenue beat(12)7
Avg Revenue beat(12)0.98%
Revenue beat(16)10
Avg Revenue beat(16)1.06%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.55 | ||
| Fwd PE | 42.16 | ||
| P/S | 1.56 | ||
| P/FCF | 12.35 | ||
| P/OCF | 11.65 | ||
| P/B | 25.36 | ||
| P/tB | 28.03 | ||
| EV/EBITDA | 16.89 |
EPS(TTM)0.33
EY5.12%
EPS(NY)0.15
Fwd EY2.37%
FCF(TTM)0.52
FCFY8.09%
OCF(TTM)0.55
OCFY8.58%
SpS4.12
BVpS0.25
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.66% | ||
| ROE | 84.15% | ||
| ROCE | 38.35% | ||
| ROIC | 30.3% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 5.29% | ||
| PM (TTM) | 5.19% | ||
| GM | 48.47% | ||
| FCFM | 12.66% |
ROA(3y)-9.62%
ROA(5y)-5.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y89.93%
OM growth 5YN/A
PM growth 3Y94.62%
PM growth 5YN/A
GM growth 3Y-1.13%
GM growth 5Y1.11%
F-Score7
Asset Turnover1.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 28.08% | ||
| Cap/Sales | 0.76% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 167.47% | ||
| Profit Quality | 243.9% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.93 | ||
| Altman-Z | 0.37 |
F-Score7
WACC10.41%
ROIC/WACC2.91
Cap/Depr(3y)65.35%
Cap/Depr(5y)124.01%
Cap/Sales(3y)2.56%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3200%
EPS 3Y146.62%
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y-50.13%
EPS Next 2Y-41.69%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.54%
Revenue growth 3Y5.06%
Revenue growth 5Y12.13%
Sales Q2Q%11.5%
Revenue Next Year5.84%
Revenue Next 2Y8.88%
Revenue Next 3Y18.44%
Revenue Next 5Y18.26%
EBIT growth 1Y199.05%
EBIT growth 3Y99.53%
EBIT growth 5YN/A
EBIT Next Year-37.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y375.86%
FCF growth 3Y19.31%
FCF growth 5Y58.93%
OCF growth 1Y4141.67%
OCF growth 3Y4.35%
OCF growth 5Y20.48%
CHAMPIONS ONCOLOGY INC / CSBR FAQ
What is the fundamental rating for CSBR stock?
ChartMill assigns a fundamental rating of 4 / 10 to CSBR.
What is the valuation status for CSBR stock?
ChartMill assigns a valuation rating of 4 / 10 to CHAMPIONS ONCOLOGY INC (CSBR). This can be considered as Fairly Valued.
What is the profitability of CSBR stock?
CHAMPIONS ONCOLOGY INC (CSBR) has a profitability rating of 6 / 10.
What is the financial health of CHAMPIONS ONCOLOGY INC (CSBR) stock?
The financial health rating of CHAMPIONS ONCOLOGY INC (CSBR) is 3 / 10.